CX-908, a PROBODY® T Cell Engager Targeting CDH3 and CD3, Induces Tumor Regressions and Improves the Therapeutic Window in Preclinical Studies

Erwan Le Scolan, Lauren Kadavy, Leila M. Boustany, Clayton White, Tiffany Tse, Sayantan Mitra, Nicole Lapuyade, Vijit Dalal, Kai-Wen Cheng, Anna F. Nguyen, Conner Bardine, Michael B. Winter, Vahideh Vakil, Sean McAllister, Robert T. Dunn, II, Vangipuram Rangan, Olga Vasiljeva, Madan Paidhungat, Marcia Belvin, Dylan Daniel; Poster presented at the Society for Immunotherapy of Cancer 2025 Annual Meeting, November 5-9, National Harbor, MD